

To: Cagen, Stuart Z SCC-HSE <stuart.cagen@shell.com>  
From: Beatty, Patrick (PatrickBeatty) <PatrickBeatty@chevrontexaco.com>  
Cc: Clegg, Patsy M SCC-CHSE-PC <patsy.clegg@shell.com>  
Bcc:  
Received Date: 2003-10-01 14:40:56 GMT  
Subject: RE: SHS

---

Thanks. This clearly an area where we can cut back if necessary.

Patrick

-----Original Message-----

From: Cagen, Stuart Z SCC-HSE [mailto:stuart.cagen@shell.com]  
Sent: Tuesday, September 30, 2003 11:29 PM  
To: Beatty, Patrick (PatrickBeatty)  
Cc: Clegg, Patsy M SCC-CHSE-PC  
Subject: SHS

Patrick:

For what it is worth, note the recent benzene biomarker study used much less than 2000 individuals to characterize dose response of benzene biomarkers - see <http://www.healtheffects.org/Pubs/Qu.pdf>

In addition, a companion HEI study with 1,3 butadiene used only 83 workers and was effective in showing dose response of butadiene exposure with biomarkers and lack of biomarkers of effect - see <http://www.healtheffects.org/Pubs/Albertini.pdf>

Stuart

Stuart Cagen

Shell Chemical LP  
One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1 713 241 1407 Fax: +1 713 241 3325 Other Tel: +1 832 646 3987  
Email: [stuart.cagen@shell.com](mailto:stuart.cagen@shell.com)  
Internet: <http://www.shell.com/chemicals>

-

---